Skip to content
★ Sign in to follow
PI

Pharmesis International Ltd. Stock: price and insider trades · Singapore

ISIN SG1BH6000003SG·Mcap SGD 3MHealth Care

No insider purchase over the last 90 days. The latest, by Fei Yang, was filed 19 Jun 2024.

Pharmesis International Ltd.: what insiders have been doing

Pharmesis International Ltd. belongs to the Health Care sector. Filings by its managers are published through SGX. Nothing new has been filed by managers of Pharmesis International Ltd. in twelve months, the latest record being from 19 June 2024.

Over the whole record (from 2017), the tally stands at 3 purchases and 3 sales.

In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. This summary is built from SGX disclosures alone and does not predict where the share price will go.

Insider Decl.
16
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
€3M
3 ops. · all time

Since the insiders bought

  • Filed 19 Jun 2024 · 872 days ago · €367k
    +305.7%
    Entry SGD 0.11 · Close at T+365 SGD 0.43
  • Filed 11 Apr 2023 · 1307 days ago · €237k
    -27.3%
    Entry SGD 0.11 · Close at T+365 SGD 0.08
  • Filed 29 Nov 2017 · 3266 days ago · €1.6M
    -21.7%
    Entry SGD 0.23 · Close at T+365 SGD 0.18

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 18,406 of 26,912 companies
39.3
score / 100
Value
50
Quality
28
FCF yld78%
Earn yld-143%
EV/EBITDA·
ROE-13%
Gross mgn36%
Net mgn-9.8%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

SGD 0.10
Analyst consensus
·
Income statement
RevenueSGD 43.8M
Gross profitSGD 15.8M36% margin
EBITDA-SGD 422k-1% margin
Net income-SGD 4.3M-25.7% margin
Valuation
P/Book0.3x
Beta-1.13
Balance sheet & cash
Market capSGD 3M
Total debtSGD 15.7M
Free Cash FlowSGD 2.4M
Debt / Equity30%
Profitability & ownership
ROE-13.1%
ROA-6.0%
% insiders78.6%
% institutions0.0%
Last declaration on 19 June 2024
Declarations16 total
  • ●
    Substantial ShareholderExecutives(filed)
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:F2LF0T6T0EGG0K9I
  • ●
    Related company / holdingExecutives
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:DGE8L06QU47E28VF
  • ●
    Related company / holdingExecutives
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:LDULVL9W7S1Y7LVF
  • ●
    Related company / holdingExecutives
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:Q3U5M0YRF3WOBE2R
  • ●
    Substantial ShareholderExecutives(filed)
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:C63XFNQDA49YMSXQ
  • ▲
    Substantial ShareholderExecutives(filed)
    533,000 SGD13SGX
    4,100,000 shares@ SGD 0.13100.0% of flowShareSGX-STISIN SG1BH6000003SGX:VF3ZKIILUZRQ5WQK
    Canonical exit: 17 Sept 2024 (T+90)
  • ●
    Related company / holdingExecutives
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:6812ANAZBCHCKOQ8
  • ●
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:1DLYHOUI2LA1NEMY
  • ●
    Related company / holdingExecutives
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:4OHT7E3G90HSHJ8W
  • ●
    Substantial ShareholderExecutives(filed)
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:70VLCWZV8J7NPF0J
  • ▲
    Substantial ShareholderExecutives(filed)
    345,000 SGD13SGX
    3,450,000 shares@ SGD 0.10100.0% of flowShareSGX-STISIN SG1BH6000003SGX:GT25R51GZHY1IMSD
    Canonical exit: 10 Jul 2023 (T+90)
  • ▼
    Related company / holdingExecutives
    0SGX
    4,770,000 sharesShareSGX-STISIN SG1BH6000003SGX:VEI973FH1817XLSJ
  • ●
    Director/CEOExecutives(filed)
    0SGX
    ShareSGX-STISIN SG1BH6000003SGX:VI59F0PLIO9WVPEC
  • ▲
    Substantial ShareholderExecutives(filed)
    3M SGD13SGX
    5,233,800 shares@ SGD 0.50100.0% of flowShareSGX-STISIN SG1BH6000003SGX:DIK442G5TEMUV2EM
    Canonical exit: 27 Feb 2018 (T+90)
  • ▼
    Director/CEOExecutives
    3M SGD42SGX
    5,233,800 shares@ SGD 0.50100.0% of flowShareSGX-STISIN SG1BH6000003SGX:VHBY96W852AWAT2O
  • ▼
    Related company / holdingExecutives(filed)
    3M SGD13SGX
    5,233,800 shares@ SGD 0.50100.0% of flowShareSGX-STISIN SG1BH6000003SGX:JS1JV9XDYZYYYJ1D

16 of 16 declarations

About Pharmesis International Ltd.

Pharmesis International Ltd. is a company listed on the XSES market, specializing in the pharmaceutical sector.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations